3D biofabrication for tubular tissue engineering

被引:0
作者
Ian Holland
Jack Logan
Jiezhong Shi
Christopher McCormick
Dongsheng Liu
Wenmiao Shu
机构
[1] University of Strathclyde,Department of Biomedical Engineering
[2] Tsinghua University,Department of Chemistry
来源
Bio-Design and Manufacturing | 2018年 / 1卷
关键词
Tubular organs; Tissue engineering; 3D printing; Bio-inks;
D O I
暂无
中图分类号
学科分类号
摘要
The therapeutic replacement of diseased tubular tissue is hindered by the availability and suitability of current donor, autologous and synthetically derived protheses. Artificially created, tissue engineered, constructs have the potential to alleviate these concerns with reduced autoimmune response, high anatomical accuracy, long-term patency and growth potential. The advent of 3D bioprinting technology has further supplemented the technological toolbox, opening up new biofabrication research opportunities and expanding the therapeutic potential of the field. In this review, we highlight the challenges facing those seeking to create artificial tubular tissue with its associated complex macro- and microscopic architecture. Current biofabrication approaches, including 3D printing techniques, are reviewed and future directions suggested.
引用
收藏
页码:89 / 100
页数:11
相关论文
共 195 条
  • [1] Basu J(2010)Platform technologies for tubular organ regeneration Trends Biotechnol 28 526-533
  • [2] Ludlow JW(2015)The tissue-engineered vascular graft–past, present, and future Tissue Eng Part B Rev 81 161-166
  • [3] Pashneh-Tala S(2008)Tissue-engineered blood vessels in pediatric cardiac surgery Yale J Biol Med 5 1-11
  • [4] MacNeil S(2014)Printing three-dimensional tissue analogues with decellularized extracellular matrix bioink Nat Commun 112 14452-14459
  • [5] Claeyssens F(2015)Regenerative medicine: current therapies and future directions Proc Natl Acad Sci 2 435-443
  • [6] Shinoka T(2013)Biomechanics and biocompatibility of the perfect conduit—can we build one? Ann Cardiothorac Surg 32 714-722
  • [7] Breuer C(2011)Implantable arterial grafts from human fibroblasts and fibrin using a multi-graft pulsed flow-stretch bioreactor with noninvasive strength monitoring Biomaterials 7 409-419
  • [8] Pati F(2012)Tissue-engineered vascular grafts for use in the treatment of congenital heart disease: from the bench to the clinic and back again Regen Med 8 43-50
  • [9] Mao AS(2007)Development of tissue engineered vascular grafts Curr Pharm Biotechnol 2 137-148
  • [10] Mooney DJ(2011)Tissue engineering of blood vessels: functional requirements, progress, and future challenges Cardiovasc Eng Technol 4 130-135